Jpmorgan Chase & CO Abeona Therapeutics Inc. Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Abeona Therapeutics Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 233,759 shares of ABEO stock, worth $1.25 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
233,759
Previous 14
1669607.14%
Holding current value
$1.25 Million
Previous $0
Infinity%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding ABEO
# of Institutions
102Shares Held
31.6MCall Options Held
2.42MPut Options Held
212K-
Nantahala Capital Management, LLC New Canaan, CT4.37MShares$23.4 Million1.08% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.07MShares$16.4 Million0.03% of portfolio
-
Suvretta Capital Management, LLC New York, NY2.68MShares$14.3 Million0.52% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.51MShares$13.4 Million0.0% of portfolio
-
Western Standard LLC Los Angeles, CA2.09MShares$11.2 Million6.61% of portfolio
About ABEONA THERAPEUTICS INC.
- Ticker ABEO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 5,950,380
- Market Cap $31.8M
- Description
- Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-a...